LIMN Stock — Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. Class A Common Stock (LIMN)

Updated October 16, 2026.

LIMN is a Stock. Total return is -99.4% over the past 5.4 years, 195.4 points behind SPY at 96.0%.

Liminatus Pharma is a pre-clinical stage biopharmaceutical company developing cancer therapies, with its lead program being IBA101, a humanized anti-CD47 monoclonal antibody currently in Phase I clinical trials for advanced solid cancers including non-small cell lung cancer. The company does not currently distribute to shareholders. This security is typical of early-stage biotech equities and appeals to investors with high risk tolerance seeking exposure to clinical-stage drug development.

LIMN performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.4% over the past 5.4 years, 195.4 points behind SPY at 96.0%. Over the past year its total return — price change plus distributions reinvested — is -95.1%. Its deepest 1-year drawdown was 97.0%.

LIMN key facts

Asset type

Stock

Asset class

Equity

Inception date

05/26/2021

Distribution frequency

None

Last close

$3.04 (as of 2026-10-16)

Market cap

$4,083,349

Average volume

16756.0

Beta

0.754

Payout ratio

0.0%

EPS

$-23.50

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LIMN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 97.0%.

Who may consider LIMN — and who may not

It is a weaker fit for investors who need monthly cash flow (LIMN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LIMN

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions